Bromocriptine for Residual Catatonia Following Neuroleptic Malignant Syndrome: Illustrative Case Report and Systematic Review
- 5 January 2025
- journal article
- review article
- Published by Elsevier in Journal of the Academy of Consultation-Liaison Psychiatry
- Vol. 66 (2) , 139-151
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Molecular and immunological origins of catatoniaSchizophrenia Research, 2023
- Brain mechanisms underlying catatonia: A systematic reviewSchizophrenia Research, 2022
- Neuroleptic Malignant Syndrome: Complications, Outcomes, and MortalityNeurocritical Care, 2015
- Antiparkinson therapeutic potencies correlate with their affinities at dopamine D2High receptorsSynapse, 2007
- Catatonia and neuroleptic malignant syndrome: psychopathology and pathophysiologyJournal of Neural Transmission, 2002
- Neuroleptic malignant syndrome with gangliosidosis type IIBiological Psychiatry, 1997
- Neuroleptic malignant syndrome and catatonia: One entity or two?Biological Psychiatry, 1996
- Amantadine increases the extracellular dopamine levels in the striatum by re-uptake inhibition and by N-methyl-d-aspartate antagonismBrain Research, 1994
- Treatment of neuroleptic malignant syndrome with levodopaHuman Psychopharmacology: Clinical and Experimental, 1992
- Neuroleptic‐induced Catatonia After Abrupt Withdrawal of Amantadine During Neuroleptic TherapyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1986